Ishibashi Naoya, Maebayashi Toshiya, Aizawa Takuya, Sakaguchi Masakuni, Nishimaki Haruna, Masuda Shinobu
Department of Radiology, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan.
Department of Pathology, Nihon University School of Medicine, Itabashi-ku, Tokyo, 173-8610, Japan.
Radiat Oncol. 2017 Jan 13;12(1):16. doi: 10.1186/s13014-016-0744-1.
In the breast cancer, the decision whether to administer adjuvant therapy is increasingly influenced by the Ki-67 proliferation index. In the present retrospective study, we investigated if this index could predict the therapeutic response to radiation therapy in small cell lung cancer (SCLC).
Data from 19 SCLC patients who received thoracic radiation therapy were included. Clinical staging was assessed using the TNM classification system (UICC, 2009; cstage IIA/IIB/IIIA/IIIB = 3/1/7/8). Ki-67 was detected using immunostained tumour sections and the Ki-67 proliferation index was determined using e-Count software. Radiation therapy was administered at total doses of 45-60 Gy. A total of 16 of the 19 patients received chemotherapy.
Patients were divided into two groups, one with a Ki-67 proliferation index ≥79.77% (group 1, 8 cases) and the other with a Ki-67 proliferation index <79.77% (group 2, 11 cases). Following radiation therapy, a complete response (CR) was observed in six cases from group 1 (75.0%) and three cases from group 2 (27.3%). The Ki-67 proliferation index was significantly correlated with the CR rate (P = 0.05), which was significantly higher in group 1 than in group 2 (P = 0.04). The median survival time was 516 days for all patients, and the survival rates did not differ significantly between groups 1 and 2.
Our study is the first to evaluate the correlation between the Ki-67 proliferation index and SCLC tumour response to radiation therapy. Our findings suggest that a high Ki-67 proliferation index might represent a predictive factor for increased tumour radiosensitivity.
在乳腺癌中，是否给予辅助治疗的决策越来越受到Ki-67增殖指数的影响。在本回顾性研究中，我们调查了该指数是否能预测小细胞肺癌（SCLC）对放射治疗的反应。
纳入19例接受胸部放射治疗的SCLC患者的数据。采用TNM分类系统（UICC，2009年；临床分期IIA/IIB/IIIA/IIIB期分别为3/1/7/8例）评估临床分期。使用免疫染色的肿瘤切片检测Ki-67，并使用e-Count软件确定Ki-67增殖指数。放射治疗的总剂量为45-60Gy。19例患者中有16例接受了化疗。
患者分为两组，一组Ki-67增殖指数≥79.77%（第1组，8例），另一组Ki-67增殖指数<79.77%（第2组，11例）。放射治疗后，第1组6例（75.0%）和第2组3例（27.3%）观察到完全缓解（CR）。Ki-67增殖指数与CR率显著相关（P=0.05），第1组的CR率显著高于第2组（P=0.04）。所有患者的中位生存时间为516天，第1组和第2组的生存率无显著差异。
我们的研究首次评估了Ki-67增殖指数与SCLC肿瘤对放射治疗反应之间的相关性。我们的研究结果表明，高Ki-67增殖指数可能是肿瘤放射敏感性增加的预测因素。
